Owing to gene amplification and regulation by transcription factors such as MYC and p53 as well as a batch of non-coding RNAs (Table 1), WWP1 is prone to overexpress in kinds of malignancies (Figure 1B), especially in breast and prostate cancers (Chen et al., 2007a,b; Nguyen Huu et al., 2008; Li et al., 2009, 2017, 2019, 2020; Tu et al., 2017; Ma et al., 2018; Tao et al., 2018; Lee et al., 2019; Zhao et al., 2019; Wang et al., 2021). Here, WWP1 is linked to prostate carcinoma.